Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
Current reports
8-K
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
9 Apr 24
8-K
Regulation FD Disclosure
29 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Departure of Directors or Certain Officers
27 Oct 23
8-K
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
28 Sep 23
8-K
Corporate Presentation September 2023
12 Sep 23
8-K
Departure of Directors or Certain Officers
4 Aug 23
8-K
Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
12 Jul 23
8-K
Other Events
21 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
14 Mar 24
SC TO-I/A
Issuer tender offer statement (amended)
11 Mar 24
SC TO-I
Issuer tender offer statement
8 Feb 24
S-3
Shelf registration
8 Nov 23
424B5
Prospectus supplement for primary offering
20 Jun 23
424B5
Prospectus supplement for primary offering
15 Jun 23
424B3
Prospectus supplement
24 Apr 23
S-3/A
Shelf registration (amended)
18 Apr 23
S-3
Shelf registration
23 Mar 23
POS AM
Prospectus update (post-effective amendment)
28 Mar 22
Proxies
DEF 14A
Definitive proxy
12 Apr 24
DEF 14A
Definitive proxy
19 Dec 23
PRE 14A
Preliminary proxy
8 Dec 23
DEF 14A
Definitive proxy
5 Apr 23
PRE 14A
Preliminary proxy
24 Mar 23
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
8 Apr 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEFA14A
Additional proxy soliciting materials
8 Apr 20
DEF 14A
Definitive proxy
8 Apr 20
Other
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
16 Nov 23
UPLOAD
Letter from SEC
14 Nov 23
EFFECT
Notice of effectiveness
25 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
CORRESP
Correspondence with SEC
18 Apr 23
UPLOAD
Letter from SEC
31 Mar 23
UPLOAD
Letter from SEC
13 Jul 22
CORRESP
Correspondence with SEC
6 Jul 22
UPLOAD
Letter from SEC
29 Jun 22